<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00429364</url>
  </required_header>
  <id_info>
    <org_study_id>461</org_study_id>
    <secondary_id>U01HL068270</secondary_id>
    <nct_id>NCT00429364</nct_id>
  </id_info>
  <brief_title>Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome--Pediatric Heart Network</brief_title>
  <official_title>Trial of Beta Blocker Therapy (Atenolol) Versus Angiotensin II Receptor Blocker Therapy (Losartan) in Individuals With Marfan Syndrome (A Trial Conducted by the Pediatric Heart Network)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New England Research Institutes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>FDA Office of Orphan Products Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Marfan Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>New England Research Institutes</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Marfan syndrome is a hereditary connective tissue disorder. Many individuals with this
      condition die because of the associated heart and blood vessel abnormalities. This study will
      compare the effectiveness of two medications, losartan and atenolol, at slowing aortic root
      enlargement in individuals with Marfan syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Marfan syndrome is an inheritable disorder that affects the body's connective tissue. An
      abnormal protein results in connective tissue that is weaker than normal. Because connective
      tissue is found throughout the body, Marfan syndrome can affect many body systems, including
      the skeleton, eyes, nervous system, skin, lungs, heart, and blood vessels. Overall, heart and
      blood vessel abnormalities are the leading cause of death in individuals with Marfan
      syndrome. A common blood vessel abnormality associated with this disease involves the aorta,
      which is the large artery that carries blood away from the heart to the rest of the body. The
      aortic root, the portion of the aorta that is attached to the heart, may enlarge and tear or
      even rupture. A tear or rupture is considered a life-threatening emergency. Recent studies
      have shown that the medication losartan may reduce aortic root growth and improve heart
      function. The purpose of this study is to compare the effectiveness of losartan versus
      atenolol at slowing aortic root growth in individuals with Marfan syndrome.

      This 3-year study will enroll individuals with Marfan syndrome. Participants will be randomly
      assigned to receive either losartan or atenolol on a daily basis. All participants will
      initially receive a low dose of their assigned medication. This dose will be gradually
      increased every 3 to 4 weeks until the maximum tolerated dose is reached. A continuous
      electrocardiogram (ECG) that monitors heart rate and activity in 24-hour intervals will be
      used to determine the proper dose increase for each participant. Participants will then
      receive the maximum tolerated dose for the remainder of the study. Study visits will occur at
      baseline and Months 6, 12, 24, and 36. Each study visit will include a physical examination,
      a medical history review, an ECG, an echocardiogram, and questionnaires. Additionally, at the
      baseline study visit blood will be collected for laboratory testing.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Annual Rate of Change in Aortic Root (Sinuses of Valsalva) Body-surface-area-adjusted Z-score</measure>
    <time_frame>Up to 3 years following randomization.</time_frame>
    <description>The rate of aortic root enlargement, expressed as the annual change in the maximum aortic-root-diameter z score indexed to body-surface area over a 3-year period following randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annual Rate of Change in Aortic Root (Sinuses of Valsalva) Absolute Dimension</measure>
    <time_frame>Up to 3 years following randomization.</time_frame>
    <description>The rate of change in the absolute dimension of the aortic root over a 3-year period following randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual Rate of Change in Ascending-aorta-diameter Z Score, Adjusted by Body-surface-area.</measure>
    <time_frame>Up to 3 years following randomization.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual Rate of Change in the Absolute Diameter of the Ascending Aorta</measure>
    <time_frame>Up to 3 years following randomization.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual Rate of Change in Aortic-annulus-diameter Z Score, Adjusted by Body-surface Area</measure>
    <time_frame>Up to 3 years following randomization.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual Rate of Change in the Absolute Diameter of the Aortic Annulus</measure>
    <time_frame>Up to 3 years following randomization.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual Rate of Change in Total Aortic Proximal Regurgitant Jet Area Indexed to Body-surface-area</measure>
    <time_frame>Up to 3 years following randomization.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual Rate of Change in Weight</measure>
    <time_frame>Up to 3 years following randomization.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual Rate of Change in Weight-for-age Z-score</measure>
    <time_frame>Up to 3 years following randomization.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual Rate of Change in Weight-for-height Z-score</measure>
    <time_frame>Up to 3 years following randomization.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual Rate of Change in Height</measure>
    <time_frame>Up to 3 years following randomization.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual Rate of Change in Height-for-age Z-score</measure>
    <time_frame>Up to 3 years following randomization.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual Rate of Change in Body Mass Index</measure>
    <time_frame>Up to 3 years following randomization.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual Rate of Change in Body Mass Index for Age Z-score</measure>
    <time_frame>Up to 3 years following randomization.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual Rate of Change in Arm Span to Height Ratio</measure>
    <time_frame>Up to 3 years following randomization.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annual Rate of Change in Upper to Lower Segment Ratio</measure>
    <time_frame>Up to 3 years following randomization.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Aortic Dissection.</measure>
    <time_frame>Up to 3 years following randomization.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Rate of Aortic Dissection.</measure>
    <time_frame>Up to 3 years following randomization.</time_frame>
    <description>Percentage of participants who had aortic dissection over a 3-year period following randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Aortic-root Surgery.</measure>
    <time_frame>Up to 3 years following randomization.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Rate of Aortic-Root Surgery</measure>
    <time_frame>Up to 3 years following randomization.</time_frame>
    <description>Percentage of participants who had aortic-root surgery over a 3-year period following randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Death.</measure>
    <time_frame>Up to 3 years following randomization.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Rate of Death</measure>
    <time_frame>Up to 3 years following randomization.</time_frame>
    <description>Percentage of participants who died over a 3-year period following randomization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With the Composite Adverse Clinical Outcomes, Including Aortic Dissection, Aortic-root Surgery and Death.</measure>
    <time_frame>Up to 3 years following randomization.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Rate of the Composite Adverse Clinical Outcomes, Including Aortic Dissection, Aortic-root Surgery and Death.</measure>
    <time_frame>Up to 3 years following randomization.</time_frame>
    <description>Percentage of participants who had aortic dissection, aortic-root surgery or death over a 3-year period following randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Drug Reactions Reported at the Baseline Visit</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Drug Reactions Reported During Routine Follow-up Surveillance</measure>
    <time_frame>From 6 months to 3 years following randomization.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">608</enrollment>
  <condition>Marfan Syndrome</condition>
  <arm_group>
    <arm_group_label>Atenolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants with Marfan's syndrome and ≥3 maximum aortic root z-score received 0.5 - 4.0 mg/kg/day Atenolol (not to exceed a total dose of 250 mg), with a goal of a 20% or greater decrease in the mean heart rate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Losartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants with Marfan's syndrome and ≥3 maximum aortic root z-score received 0.4 - 1.4 mg/kg/day Losartan (not to exceed a total dose of 100 mg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan Potassium</intervention_name>
    <description>Losartan .3 - 1.4 mg/kg</description>
    <arm_group_label>Losartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atenolol</intervention_name>
    <description>Atenolol .5 - 4 mg/kg</description>
    <arm_group_label>Atenolol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Marfan syndrome, according to Ghent criteria (more information can be
             found in Appendix D of the protocol)

          -  Aortic root Z-score greater than 3.0

        Exclusion Criteria:

          -  Prior aortic surgery

          -  Aortic root dimension at the sinuses of Valsalva greater than 5 cm

          -  Planned aortic surgery within 6 months of study entry

          -  Aortic dissection

          -  Shprintzen-Goldberg syndrome

          -  Loeys-Dietz syndrome

          -  Therapeutic (i.e., for arrhythmia, ventricular dysfunction, or valve regurgitation)
             rather than prophylactic use of angiotensin-converting enzyme (ACE) inhibitor,
             beta-blocker, or calcium channel blocker

          -  History of angioedema while taking an ACE inhibitor or beta-blocker

          -  Intolerance to losartan or other angiotensin II receptor blocker (ARB) that resulted
             in termination of therapy

          -  Intolerance to atenolol or other beta-blocker that resulted in termination of therapy

          -  Kidney dysfunction (i.e., creatinine greater than the upper limit of age-related
             normal values)

          -  Asthma of sufficient severity to prohibit the use of a beta-blocker

          -  Chronic use of steroids and/or beta-adrenergic agents with exacerbations of asthma
             that are frequent (averaging three or more per year) or severe (requiring
             hospitalization)

          -  Diabetes mellitus

          -  Pregnant or planning to become pregnant within 36 months of study entry

          -  Inability to complete study procedures, including history of poor acoustic windows
             (i.e., inability to obtain accurate measurement of aortic root)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ron Lacro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Children’s Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital / UCSD</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Minnesota - St. Paul</name>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Medical College of Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia College of Physicians and Surgeons</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brody School of Medicine at East Carolina University</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Children's Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ghent University Hospital</name>
      <address>
        <city>De Pintelaan</city>
        <state>Gent</state>
        <zip>185 9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.pediatricheartnetwork.org</url>
    <description>Click here for the Pediatric Heart Network Web site</description>
  </link>
  <link>
    <url>http://www.marfan.org</url>
    <description>Click here for the National Marfan Foundation Web site</description>
  </link>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2007</study_first_submitted>
  <study_first_submitted_qc>January 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2007</study_first_posted>
  <results_first_submitted>February 25, 2015</results_first_submitted>
  <results_first_submitted_qc>March 17, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 1, 2015</results_first_posted>
  <last_update_submitted>March 17, 2015</last_update_submitted>
  <last_update_submitted_qc>March 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aortic Root Dissection</keyword>
  <keyword>Aortic Root Dilation</keyword>
  <keyword>Pediatric Heart Network</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Marfan Syndrome</mesh_term>
    <mesh_term>Arachnodactyly</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Atenolol</mesh_term>
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From January 2007 through February 2011, a total of 21 clinical centers enrolled 608 participants into the study.</recruitment_details>
      <pre_assignment_details>For subjects on prophylactic therapy with atenolol or other BB, ARB, ACEi, or calcium-channel blocker, before the study, the drug will be weaned over a 14-day period. After that, a drug washout period of 14–21 days will take place before baseline assessment and randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Atenolol</title>
          <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.5 - 4.0 mg/kg/day Atenolol (not to exceed a total dose of 250 mg), with a goal of a 20% or greater decrease in the mean heart rate.</description>
        </group>
        <group group_id="P2">
          <title>Losartan</title>
          <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.4 - 1.4 mg/kg/day Losartan (not to exceed a total dose of 100 mg).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="303"/>
                <participants group_id="P2" count="305"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="271"/>
                <participants group_id="P2" count="272"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Underwent aortic root surgery</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Atenolol</title>
          <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.5 - 4.0 mg/kg/day Atenolol (not to exceed a total dose of 250 mg), with a goal of a 20% or greater decrease in the mean heart rate.</description>
        </group>
        <group group_id="B2">
          <title>Losartan</title>
          <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.4 - 1.4 mg/kg/day Losartan (not to exceed a total dose of 100 mg).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="303"/>
            <count group_id="B2" value="305"/>
            <count group_id="B3" value="608"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.5" spread="6.5"/>
                    <measurement group_id="B2" value="11.0" spread="6.2"/>
                    <measurement group_id="B3" value="11.2" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <description>Young adults were defined as male participants who were 16 to 25 years of age and female participants who were 15 to 25 years of age.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Young adult</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Child</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="227"/>
                    <measurement group_id="B2" value="230"/>
                    <measurement group_id="B3" value="457"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="123"/>
                    <measurement group_id="B2" value="119"/>
                    <measurement group_id="B3" value="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="180"/>
                    <measurement group_id="B2" value="186"/>
                    <measurement group_id="B3" value="366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <description>Data on race and ethnicity provided by the participant or a family member at the time of enrollment.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="266"/>
                    <measurement group_id="B2" value="259"/>
                    <measurement group_id="B3" value="525"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Data on race and ethnicity provided by the participant or a family member at the time of enrollment.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="266"/>
                    <measurement group_id="B2" value="260"/>
                    <measurement group_id="B3" value="526"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Presence of causal FBN1 mutation</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="201"/>
                    <measurement group_id="B2" value="202"/>
                    <measurement group_id="B3" value="403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Family history of Marfan</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="180"/>
                    <measurement group_id="B2" value="181"/>
                    <measurement group_id="B3" value="361"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Maximum aortic-root diameter, cm</title>
          <description>Data are based on readings at a central echocardiographic laboratory. Echocardiographic data were missing for one participant in the losartan group because of an unreadable echocardiogram.</description>
          <units>centimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.4" spread="0.7"/>
                    <measurement group_id="B2" value="3.4" spread="0.7"/>
                    <measurement group_id="B3" value="3.4" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Maximum aortic-root diameter z-score</title>
          <description>Data are based on readings at a central echocardiographic laboratory. Echocardiographic data were missing for one participant in the losartan group because of an unreadable echocardiogram.</description>
          <units>z-score</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.0" lower_limit="3.5" upper_limit="4.8"/>
                    <measurement group_id="B2" value="4.0" lower_limit="3.3" upper_limit="5.0"/>
                    <measurement group_id="B3" value="4.0" lower_limit="3.4" upper_limit="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Maximum aortic-root diameter z-score</title>
          <description>Data are based on readings at a central echocardiographic laboratory. Echocardiographic data were missing for one participant in the losartan group because of an unreadable echocardiogram.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>≥z-score of 4.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&lt;z-score of 4.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="197"/>
                    <measurement group_id="B2" value="191"/>
                    <measurement group_id="B3" value="388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Had medical history of cardiac surgery</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="297"/>
                    <measurement group_id="B2" value="299"/>
                    <measurement group_id="B3" value="596"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Had medical history of cardiovascular disorder</title>
          <description>Cardiovascular disorder was defined by exercise intolerance, syncope; arrhythmia, hypertension, or hypotension requiring therapy; chest pain, shortness of breath; or other cardiovascular conditions.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="264"/>
                    <measurement group_id="B2" value="269"/>
                    <measurement group_id="B3" value="533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior use of beta-blocker</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="173"/>
                    <measurement group_id="B2" value="171"/>
                    <measurement group_id="B3" value="344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                    <measurement group_id="B2" value="134"/>
                    <measurement group_id="B3" value="264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Had medical history of endocrine disorder</title>
          <description>Endocrine disorder was defined by either the use of hormone therapy to limit growth, delayed puberty.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="296"/>
                    <measurement group_id="B2" value="305"/>
                    <measurement group_id="B3" value="601"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Had medical history of neurodevelopmental disorder</title>
          <description>Neurodevelopmental disorder was defined as attention deficit-hyperactivity disorder requiring therapy, developmental delay requiring therapy, learning disability requiring services, or other neurodevelopmental conditions.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="247"/>
                    <measurement group_id="B2" value="244"/>
                    <measurement group_id="B3" value="491"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Had medical history of psychiatric disorder</title>
          <description>Psychiatric disorder was defined as depression requiring therapy, anxiety, or other psychiatric conditions.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="280"/>
                    <measurement group_id="B2" value="289"/>
                    <measurement group_id="B3" value="569"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Annual Rate of Change in Aortic Root (Sinuses of Valsalva) Body-surface-area-adjusted Z-score</title>
        <description>The rate of aortic root enlargement, expressed as the annual change in the maximum aortic-root-diameter z score indexed to body-surface area over a 3-year period following randomization</description>
        <time_frame>Up to 3 years following randomization.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.5 - 4.0 mg/kg/day Atenolol (not to exceed a total dose of 250 mg), with a goal of a 20% or greater decrease in the mean heart rate.</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.4 - 1.4 mg/kg/day Losartan (not to exceed a total dose of 100 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Rate of Change in Aortic Root (Sinuses of Valsalva) Body-surface-area-adjusted Z-score</title>
          <description>The rate of aortic root enlargement, expressed as the annual change in the maximum aortic-root-diameter z score indexed to body-surface area over a 3-year period following randomization</description>
          <units>z-score/year</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.139" spread="0.013"/>
                    <measurement group_id="O2" value="-0.107" spread="0.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.08</p_value>
            <p_value_desc>P values are based on a linear regression mixed-effect model comparing slopes under compound symmetry, with adjustment for baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual Rate of Change in Aortic Root (Sinuses of Valsalva) Absolute Dimension</title>
        <description>The rate of change in the absolute dimension of the aortic root over a 3-year period following randomization</description>
        <time_frame>Up to 3 years following randomization.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.5 - 4.0 mg/kg/day Atenolol (not to exceed a total dose of 250 mg), with a goal of a 20% or greater decrease in the mean heart rate.</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.4 - 1.4 mg/kg/day Losartan (not to exceed a total dose of 100 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Rate of Change in Aortic Root (Sinuses of Valsalva) Absolute Dimension</title>
          <description>The rate of change in the absolute dimension of the aortic root over a 3-year period following randomization</description>
          <units>cm/year</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.069" spread="0.004"/>
                    <measurement group_id="O2" value="0.075" spread="0.004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.20</p_value>
            <p_value_desc>P values are based on a linear regression mixed-effect model comparing slopes under compound symmetry, with adjustment for baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual Rate of Change in Ascending-aorta-diameter Z Score, Adjusted by Body-surface-area.</title>
        <time_frame>Up to 3 years following randomization.</time_frame>
        <population>All randomized participants whose ascending-aorta-diameter z scores were measured at baseline and at any of the follow-up visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.5 - 4.0 mg/kg/day Atenolol (not to exceed a total dose of 250 mg), with a goal of a 20% or greater decrease in the mean heart rate.</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.4 - 1.4 mg/kg/day Losartan (not to exceed a total dose of 100 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Rate of Change in Ascending-aorta-diameter Z Score, Adjusted by Body-surface-area.</title>
          <population>All randomized participants whose ascending-aorta-diameter z scores were measured at baseline and at any of the follow-up visits.</population>
          <units>z-score/year</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="296"/>
                <count group_id="O2" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.140" spread="0.013"/>
                    <measurement group_id="O2" value="-0.114" spread="0.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.15</p_value>
            <p_value_desc>P values are based on a linear regression mixed-effect model comparing slopes under compound symmetry, with adjustment for baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual Rate of Change in the Absolute Diameter of the Ascending Aorta</title>
        <time_frame>Up to 3 years following randomization.</time_frame>
        <population>All randomized participants whose absolute dimensions of the ascending aorta were measured at baseline and at any of the follow-up visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.5 - 4.0 mg/kg/day Atenolol (not to exceed a total dose of 250 mg), with a goal of a 20% or greater decrease in the mean heart rate.</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.4 - 1.4 mg/kg/day Losartan (not to exceed a total dose of 100 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Rate of Change in the Absolute Diameter of the Ascending Aorta</title>
          <population>All randomized participants whose absolute dimensions of the ascending aorta were measured at baseline and at any of the follow-up visits.</population>
          <units>cm/year</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="296"/>
                <count group_id="O2" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.039" spread="0.004"/>
                    <measurement group_id="O2" value="0.044" spread="0.004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.30</p_value>
            <p_value_desc>P values are based on a linear regression mixed-effect model comparing slopes under compound symmetry, with adjustment for baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual Rate of Change in Aortic-annulus-diameter Z Score, Adjusted by Body-surface Area</title>
        <time_frame>Up to 3 years following randomization.</time_frame>
        <population>All randomized participants whose aortic-annulus-diameter z scores were measured at baseline and at any of the follow-up visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.5 - 4.0 mg/kg/day Atenolol (not to exceed a total dose of 250 mg), with a goal of a 20% or greater decrease in the mean heart rate.</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.4 - 1.4 mg/kg/day Losartan (not to exceed a total dose of 100 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Rate of Change in Aortic-annulus-diameter Z Score, Adjusted by Body-surface Area</title>
          <population>All randomized participants whose aortic-annulus-diameter z scores were measured at baseline and at any of the follow-up visits.</population>
          <units>z-score/year</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.279" spread="0.018"/>
                    <measurement group_id="O2" value="-0.175" spread="0.018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P values are based on a linear regression mixed-effect model comparing slopes under compound symmetry, with adjustment for baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual Rate of Change in the Absolute Diameter of the Aortic Annulus</title>
        <time_frame>Up to 3 years following randomization.</time_frame>
        <population>All randomized participants whose absolute dimensions of the aortic annulus were measured at baseline and at any of the follow-up visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.5 - 4.0 mg/kg/day Atenolol (not to exceed a total dose of 250 mg), with a goal of a 20% or greater decrease in the mean heart rate.</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.4 - 1.4 mg/kg/day Losartan (not to exceed a total dose of 100 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Rate of Change in the Absolute Diameter of the Aortic Annulus</title>
          <population>All randomized participants whose absolute dimensions of the aortic annulus were measured at baseline and at any of the follow-up visits.</population>
          <units>cm/year</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="302"/>
                <count group_id="O2" value="304"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.015" spread="0.003"/>
                    <measurement group_id="O2" value="0.030" spread="0.003"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <p_value_desc>P values are based on a linear regression mixed-effect model comparing slopes under compound symmetry, with adjustment for baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual Rate of Change in Total Aortic Proximal Regurgitant Jet Area Indexed to Body-surface-area</title>
        <time_frame>Up to 3 years following randomization.</time_frame>
        <population>All randomized participants whose total aortic proximal regurgitant jet area indexes were measured at baseline or at any of the follow-up visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.5 - 4.0 mg/kg/day Atenolol (not to exceed a total dose of 250 mg), with a goal of a 20% or greater decrease in the mean heart rate.</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.4 - 1.4 mg/kg/day Losartan (not to exceed a total dose of 100 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Rate of Change in Total Aortic Proximal Regurgitant Jet Area Indexed to Body-surface-area</title>
          <population>All randomized participants whose total aortic proximal regurgitant jet area indexes were measured at baseline or at any of the follow-up visits.</population>
          <units>(mm^2/m^2)/year</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="301"/>
                <count group_id="O2" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.005" spread="0.003"/>
                    <measurement group_id="O2" value="0.001" spread="0.003"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.29</p_value>
            <p_value_desc>P values are based on a linear regression mixed-effect model comparing slopes under compound symmetry, with adjustment for baseline.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual Rate of Change in Weight</title>
        <time_frame>Up to 3 years following randomization.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.5 - 4.0 mg/kg/day Atenolol (not to exceed a total dose of 250 mg), with a goal of a 20% or greater decrease in the mean heart rate.</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.4 - 1.4 mg/kg/day Losartan (not to exceed a total dose of 100 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Rate of Change in Weight</title>
          <units>kg/year</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.239" spread="0.153"/>
                    <measurement group_id="O2" value="0.229" spread="0.154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.96</p_value>
            <p_value_desc>Regression model adjusted for age at study visit.</p_value_desc>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual Rate of Change in Weight-for-age Z-score</title>
        <time_frame>Up to 3 years following randomization.</time_frame>
        <population>All randomized participants who were between 0-20 years of age and whose weight-for-age z-scores were measured at baseline and at any of the follow-up visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.5 - 4.0 mg/kg/day Atenolol (not to exceed a total dose of 250 mg), with a goal of a 20% or greater decrease in the mean heart rate.</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.4 - 1.4 mg/kg/day Losartan (not to exceed a total dose of 100 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Rate of Change in Weight-for-age Z-score</title>
          <population>All randomized participants who were between 0-20 years of age and whose weight-for-age z-scores were measured at baseline and at any of the follow-up visits.</population>
          <units>z-score/year</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="270"/>
                <count group_id="O2" value="278"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.011" spread="0.013"/>
                    <measurement group_id="O2" value="0.019" spread="0.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.45</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual Rate of Change in Weight-for-height Z-score</title>
        <time_frame>Up to 3 years following randomization.</time_frame>
        <population>All randomized participants who were &lt;120 cm in heights and whose weight-for-height z-scores were measured at baseline or at any of the follow-up visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.5 - 4.0 mg/kg/day Atenolol (not to exceed a total dose of 250 mg), with a goal of a 20% or greater decrease in the mean heart rate.</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.4 - 1.4 mg/kg/day Losartan (not to exceed a total dose of 100 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Rate of Change in Weight-for-height Z-score</title>
          <population>All randomized participants who were &lt;120 cm in heights and whose weight-for-height z-scores were measured at baseline or at any of the follow-up visits.</population>
          <units>z-score/year</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.001" spread="0.072"/>
                    <measurement group_id="O2" value="-0.157" spread="0.076"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.13</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual Rate of Change in Height</title>
        <time_frame>Up to 3 years following randomization.</time_frame>
        <population>All randomized participants whose heights were measured at baseline and at any of the follow-up visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.5 - 4.0 mg/kg/day Atenolol (not to exceed a total dose of 250 mg), with a goal of a 20% or greater decrease in the mean heart rate.</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.4 - 1.4 mg/kg/day Losartan (not to exceed a total dose of 100 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Rate of Change in Height</title>
          <population>All randomized participants whose heights were measured at baseline and at any of the follow-up visits.</population>
          <units>cm/year</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.822" spread="0.204"/>
                    <measurement group_id="O2" value="0.935" spread="0.202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.65</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual Rate of Change in Height-for-age Z-score</title>
        <time_frame>Up to 3 years following randomization.</time_frame>
        <population>All randomized participants who were between 0-20 years of age and whose heights were measured at baseline and at any of the follow-up visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.5 - 4.0 mg/kg/day Atenolol (not to exceed a total dose of 250 mg), with a goal of a 20% or greater decrease in the mean heart rate.</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.4 - 1.4 mg/kg/day Losartan (not to exceed a total dose of 100 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Rate of Change in Height-for-age Z-score</title>
          <population>All randomized participants who were between 0-20 years of age and whose heights were measured at baseline and at any of the follow-up visits.</population>
          <units>z-score/year</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="269"/>
                <count group_id="O2" value="272"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.046" spread="0.013"/>
                    <measurement group_id="O2" value="0.019" spread="0.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.13</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual Rate of Change in Body Mass Index</title>
        <time_frame>Up to 3 years following randomization.</time_frame>
        <population>All randomized participants whose body mass indexes were measured at baseline and at any of the follow-up visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.5 - 4.0 mg/kg/day Atenolol (not to exceed a total dose of 250 mg), with a goal of a 20% or greater decrease in the mean heart rate.</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.4 - 1.4 mg/kg/day Losartan (not to exceed a total dose of 100 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Rate of Change in Body Mass Index</title>
          <population>All randomized participants whose body mass indexes were measured at baseline and at any of the follow-up visits.</population>
          <units>kg/m^2 per year</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="283"/>
                <count group_id="O2" value="295"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.063" spread="0.044"/>
                    <measurement group_id="O2" value="0.076" spread="0.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.82</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual Rate of Change in Body Mass Index for Age Z-score</title>
        <time_frame>Up to 3 years following randomization.</time_frame>
        <population>All randomized participants who were between 0-20 years of age and whose body mass index for age z-scores were measured at baseline and at any of the follow-up visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.5 - 4.0 mg/kg/day Atenolol (not to exceed a total dose of 250 mg), with a goal of a 20% or greater decrease in the mean heart rate.</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.4 - 1.4 mg/kg/day Losartan (not to exceed a total dose of 100 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Rate of Change in Body Mass Index for Age Z-score</title>
          <population>All randomized participants who were between 0-20 years of age and whose body mass index for age z-scores were measured at baseline and at any of the follow-up visits.</population>
          <units>z-score/year</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="250"/>
                <count group_id="O2" value="263"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.007" spread="0.022"/>
                    <measurement group_id="O2" value="0.021" spread="0.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.64</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual Rate of Change in Arm Span to Height Ratio</title>
        <time_frame>Up to 3 years following randomization.</time_frame>
        <population>All randomized participants whose arm span to height ratios were measured at baseline and at any of the follow-up visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.5 - 4.0 mg/kg/day Atenolol (not to exceed a total dose of 250 mg), with a goal of a 20% or greater decrease in the mean heart rate.</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.4 - 1.4 mg/kg/day Losartan (not to exceed a total dose of 100 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Rate of Change in Arm Span to Height Ratio</title>
          <population>All randomized participants whose arm span to height ratios were measured at baseline and at any of the follow-up visits.</population>
          <units>1/year</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="301"/>
                <count group_id="O2" value="303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.001" spread="0.001"/>
                    <measurement group_id="O2" value="0.001" spread="0.001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.49</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Annual Rate of Change in Upper to Lower Segment Ratio</title>
        <time_frame>Up to 3 years following randomization.</time_frame>
        <population>All randomized participants whose upper to lower segment ratios were measured at baseline and at any of the follow-up visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.5 - 4.0 mg/kg/day Atenolol (not to exceed a total dose of 250 mg), with a goal of a 20% or greater decrease in the mean heart rate.</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.4 - 1.4 mg/kg/day Losartan (not to exceed a total dose of 100 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Annual Rate of Change in Upper to Lower Segment Ratio</title>
          <population>All randomized participants whose upper to lower segment ratios were measured at baseline and at any of the follow-up visits.</population>
          <units>1/year</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="301"/>
                <count group_id="O2" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.014" spread="0.002"/>
                    <measurement group_id="O2" value="-0.015" spread="0.002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.59</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Aortic Dissection.</title>
        <time_frame>Up to 3 years following randomization.</time_frame>
        <population>All randomized participants who received the treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.5 - 4.0 mg/kg/day Atenolol (not to exceed a total dose of 250 mg), with a goal of a 20% or greater decrease in the mean heart rate.</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.4 - 1.4 mg/kg/day Losartan (not to exceed a total dose of 100 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Aortic Dissection.</title>
          <population>All randomized participants who received the treatment</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event Rate of Aortic Dissection.</title>
        <description>Percentage of participants who had aortic dissection over a 3-year period following randomization.</description>
        <time_frame>Up to 3 years following randomization.</time_frame>
        <population>All randomized participants who received the treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.5 - 4.0 mg/kg/day Atenolol (not to exceed a total dose of 250 mg), with a goal of a 20% or greater decrease in the mean heart rate.</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.4 - 1.4 mg/kg/day Losartan (not to exceed a total dose of 100 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Event Rate of Aortic Dissection.</title>
          <description>Percentage of participants who had aortic dissection over a 3-year period following randomization.</description>
          <population>All randomized participants who received the treatment</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0.7" lower_limit="0.2" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.16</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Aortic-root Surgery.</title>
        <time_frame>Up to 3 years following randomization.</time_frame>
        <population>All randomized participants who received the treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.5 - 4.0 mg/kg/day Atenolol (not to exceed a total dose of 250 mg), with a goal of a 20% or greater decrease in the mean heart rate.</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.4 - 1.4 mg/kg/day Losartan (not to exceed a total dose of 100 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Aortic-root Surgery.</title>
          <population>All randomized participants who received the treatment</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event Rate of Aortic-Root Surgery</title>
        <description>Percentage of participants who had aortic-root surgery over a 3-year period following randomization.</description>
        <time_frame>Up to 3 years following randomization.</time_frame>
        <population>All randomized participants who received the treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.5 - 4.0 mg/kg/day Atenolol (not to exceed a total dose of 250 mg), with a goal of a 20% or greater decrease in the mean heart rate.</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.4 - 1.4 mg/kg/day Losartan (not to exceed a total dose of 100 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Event Rate of Aortic-Root Surgery</title>
          <description>Percentage of participants who had aortic-root surgery over a 3-year period following randomization.</description>
          <population>All randomized participants who received the treatment</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="1.9" upper_limit="6.3"/>
                    <measurement group_id="O2" value="6.0" lower_limit="3.8" upper_limit="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.13</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Death.</title>
        <time_frame>Up to 3 years following randomization.</time_frame>
        <population>All randomized participants who received the treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.5 - 4.0 mg/kg/day Atenolol (not to exceed a total dose of 250 mg), with a goal of a 20% or greater decrease in the mean heart rate.</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.4 - 1.4 mg/kg/day Losartan (not to exceed a total dose of 100 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Death.</title>
          <population>All randomized participants who received the treatment</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event Rate of Death</title>
        <description>Percentage of participants who died over a 3-year period following randomization.</description>
        <time_frame>Up to 3 years following randomization.</time_frame>
        <population>All randomized participants who received the treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.5 - 4.0 mg/kg/day Atenolol (not to exceed a total dose of 250 mg), with a goal of a 20% or greater decrease in the mean heart rate.</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.4 - 1.4 mg/kg/day Losartan (not to exceed a total dose of 100 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Event Rate of Death</title>
          <description>Percentage of participants who died over a 3-year period following randomization.</description>
          <population>All randomized participants who received the treatment</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0.3" lower_limit="0" upper_limit="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.32</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With the Composite Adverse Clinical Outcomes, Including Aortic Dissection, Aortic-root Surgery and Death.</title>
        <time_frame>Up to 3 years following randomization.</time_frame>
        <population>All randomized participants who received the treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.5 - 4.0 mg/kg/day Atenolol (not to exceed a total dose of 250 mg), with a goal of a 20% or greater decrease in the mean heart rate.</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.4 - 1.4 mg/kg/day Losartan (not to exceed a total dose of 100 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With the Composite Adverse Clinical Outcomes, Including Aortic Dissection, Aortic-root Surgery and Death.</title>
          <population>All randomized participants who received the treatment</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event Rate of the Composite Adverse Clinical Outcomes, Including Aortic Dissection, Aortic-root Surgery and Death.</title>
        <description>Percentage of participants who had aortic dissection, aortic-root surgery or death over a 3-year period following randomization</description>
        <time_frame>Up to 3 years following randomization.</time_frame>
        <population>All randomized participants who received the treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.5 - 4.0 mg/kg/day Atenolol (not to exceed a total dose of 250 mg), with a goal of a 20% or greater decrease in the mean heart rate.</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.4 - 1.4 mg/kg/day Losartan (not to exceed a total dose of 100 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Event Rate of the Composite Adverse Clinical Outcomes, Including Aortic Dissection, Aortic-root Surgery and Death.</title>
          <description>Percentage of participants who had aortic dissection, aortic-root surgery or death over a 3-year period following randomization</description>
          <population>All randomized participants who received the treatment</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="1.9" upper_limit="6.3"/>
                    <measurement group_id="O2" value="6.4" lower_limit="4.1" upper_limit="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.10</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Drug Reactions Reported at the Baseline Visit</title>
        <time_frame>At baseline</time_frame>
        <population>All randomized participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.5 - 4.0 mg/kg/day Atenolol (not to exceed a total dose of 250 mg), with a goal of a 20% or greater decrease in the mean heart rate.</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.4 - 1.4 mg/kg/day Losartan (not to exceed a total dose of 100 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Drug Reactions Reported at the Baseline Visit</title>
          <population>All randomized participants.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="303"/>
                <count group_id="O2" value="305"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Headache, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mood alterations, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mood alterations, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Behavior changes, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Behavior changes, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nightmares, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nightmares, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dizziness with standing, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dizziness with standing, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dizziness - other, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dizziness - other, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fainting with loss of consciousness, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fainting with loss of consciousness, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Palpitations, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Palpitations, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest pain, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest pain, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnea, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnea, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wheezing, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wheezing, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper respiratory/Nasal congestion, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper respiratory/Nasal congestion, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dysgeusia, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dysgeusia, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stomach pain/Indigestion, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stomach pain/Indigestion, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vascular (hands, feet), any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vascular (hands, feet), bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle pain or Cramps, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle pain or Cramps, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Back pain, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Back pain, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Periorbital edema, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Periorbital edema, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pedal edema, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pedal edema, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Drug Reactions Reported During Routine Follow-up Surveillance</title>
        <time_frame>From 6 months to 3 years following randomization.</time_frame>
        <population>All subjects who had any of the follow-up visits after 6 months post-randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Atenolol</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.5 - 4.0 mg/kg/day Atenolol (not to exceed a total dose of 250 mg), with a goal of a 20% or greater decrease in the mean heart rate.</description>
          </group>
          <group group_id="O2">
            <title>Losartan</title>
            <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.4 - 1.4 mg/kg/day Losartan (not to exceed a total dose of 100 mg).</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Drug Reactions Reported During Routine Follow-up Surveillance</title>
          <population>All subjects who had any of the follow-up visits after 6 months post-randomization.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="297"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Headache, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="202"/>
                    <measurement group_id="O2" value="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152"/>
                    <measurement group_id="O2" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mood alterations, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mood alterations, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Behavior changes, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Behavior changes, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insomnia, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nightmares, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nightmares, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dizziness with standing, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                    <measurement group_id="O2" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dizziness with standing, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dizziness - other, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dizziness - other, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fainting with loss of consciousness, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fainting with loss of consciousness, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Palpitations, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Palpitations, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest pain, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest pain, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnea, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspnea, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wheezing, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wheezing, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper respiratory/Nasal congestion, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188"/>
                    <measurement group_id="O2" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper respiratory/Nasal congestion, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                    <measurement group_id="O2" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cough, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dysgeusia, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dysgeusia, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stomach pain/Indigestion, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                    <measurement group_id="O2" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stomach pain/Indigestion, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vascular (hands, feet), any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vascular (hands, feet), bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle pain or Cramps, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148"/>
                    <measurement group_id="O2" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle pain or Cramps, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Back pain, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137"/>
                    <measurement group_id="O2" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Back pain, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Periorbital edema, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Periorbital edema, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pedal edema, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pedal edema, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other, any severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other, bothersome</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The adverse event (AE) data were collected since randomization till the end of the study, for up to 3 years.</time_frame>
      <desc>Serious AEs and important medical events (including pregnancy) were reported within 24 hours of first knowledge of event; Non-Serious AEs were reported within 7 calendar days of first knowledge of event.</desc>
      <group_list>
        <group group_id="E1">
          <title>Atenolol</title>
          <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.5 - 4.0 mg/kg/day Atenolol (not to exceed a total dose of 250 mg), with a goal of a 20% or greater decrease in the mean heart rate.</description>
        </group>
        <group group_id="E2">
          <title>Losartan</title>
          <description>Participants with Marfan’s syndrome and ≥3 maximum aortic root z-score received 0.4 - 1.4 mg/kg/day Losartan (not to exceed a total dose of 100 mg).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE 3.0 MedDRA 6.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood/bone marrow(sickle cell crisis)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pericarditis NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Valvular heart disease NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Diarrhoea NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pancreatitis NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune disorder NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hypersensitivity NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Serum sickness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Soft tissue infection NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Urinary tract infection NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Wound - snake bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Vascular: vessel injury-artery, other NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Scoliosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Convulsions NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Psychosis aggravated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urethral obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pneumonitis NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pneumothorax NOS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="303"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pulmonary/upper respiratory-other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Culture wound negative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Aortic root enlargement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Cardiac General-other: mitral valve replacement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE 3.0 MedDRA 6.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="135" subjects_at_risk="303"/>
                <counts group_id="E2" subjects_affected="121" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Haemoglobin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Lymph node pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac General - Other - Murmur</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Cardiac General - other - nonresponsive and pale</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="303"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Auditory/ear-other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hypersensitivity to sound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flushes NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Eyelid function disorder NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Ocular-other (L eye burning/redness 4 mos. s/p lensectomy with lens insertion)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Ocular-other (right eye hemorrhage)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Ocular/Visual - Squinting of OS to see things more clearly.</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Ocular/visual-other (redness and itching of eyes)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Photopsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain NOS</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="303"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="303"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Diarrhoea NOS</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="303"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="303"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Gastrointestinal - HERNIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Intestinal Hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Oesophageal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Oseophagitis NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Peridontal disorder NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Stomach discomfort</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="303"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Tooth disorder NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Vomiting NOS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Bilateral pedal edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="303"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Constitutional symptoms -other(flu)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Constitutional symptoms-other (unusual dreams)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Constitutional-other (general body cold sensation)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Edema:head and neck</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Edema:limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Falling asleep</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="303"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Influenza-like illness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="303"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pain-other (right hip pain)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pain-other:chest pain/costochondritis (diagnosed in ER as costochondritis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="303"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy/Immunology - Other (rash)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hypersensitivity NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abcessed tooth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Bronchitis NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Gum infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Infection - Eye NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Infection - Other - Parvovirus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Infection Pharnyx</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC-eye, NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC-middle ear</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC-pharynx</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC-sinus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Infection with unknown ANC-upper ariway NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Infection-bladder(urinary)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Infection-other (sinus, bronchitis, pharyngeal)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Infection-other (skin on foot)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Infection-other-Lyme disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Infection: Dental - Tooth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Middle ear infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Mononucleosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Shingles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Sinus infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Sinusitis NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Urinary tract infection NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Vaginitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Viral infection coxsackievirus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="303"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="303"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="303"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Joint disorder NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Msk/soft tissue, other (Nodule on back)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Muscle weakness, generalized or specific area</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Musculoskeletal (other) (loose joints-causing pain)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Musculoskeletal/soft tissue - other (patellar dislocation)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Musculoskeletal/soft tissue-other (Bursa on left shoulder blade due to back brace)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Musculoskeletal/soft tissue-other (nodule on back)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Musculoskeletal/soft tissue-other( left arm pain)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="303"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="303"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Convulsions NOS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="303"/>
                <counts group_id="E2" events="18" subjects_affected="17" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Dizziness upon standing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="36" subjects_affected="31" subjects_at_risk="303"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Neuralgia NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Neurology - other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Neurology-other (panic attacks)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Panick attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="303"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Sexual/reproductive function-other (4.5 cm cyst on right ovary)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Sexual/reproductive function-other (abnormal pap smear)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="303"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="303"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="303"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="303"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Mood alteration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Neurology-other (expression of anger and sadness)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Neurology-other (irritability)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Personality change</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="303"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Chromaturia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Renal/genitourinary-increased urinary frequency, daytime only, associated w/ po water intake</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Urogenital haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Gynaecomastia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="303"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="303"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="303"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="303"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hemorrhage/Bleeding - other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Nasal conjestion/inf with unk ANC upper airway NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Obstructive sleep apnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pulmonary/upper respiratory-other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Upper Respiratory - Other</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Burn on skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Derm/skin-other (Poison Ivy)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Derm/skin-other (mild chin rash)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Derm/skin-other (possible aczema)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Derm/skin-other (worsening of underlying hand skin disorder)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Dermatitis exfoliative NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Dermatology - other - Erythema Nodosum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Dermatology/skin-other (Poison Ivy)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Dermatology/skin-other (cervical dysplasia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Dermatology/skin-other (papules on legs)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Dermatology/skin-other (rash: nonspecific maculopapular rash)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Rash on torso and neck</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Sweating increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Urticaria NOS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="303"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cardiac general-chest tightness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hypertension NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="303"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Hypotension NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Raynaud's Phenomena</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="303"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="305"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All publications and presentations resulting from studies from the PHN Network must be approved by the Publications and Presentations Committee before submission. The Sponsor (NERI) and funding agency (NHLBI) both are represented on the P&amp;P Committee along with Network Investigators. Members of the P&amp;P Committee can recommend changes to publications.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The effect of losartan on TGF-β was not assessed. The study results do not apply to Marfan subjects whose BSA–adj. aortic-root z score is ≤3.
Subjects may find their treatment based on the appearance of the drug.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Paul Stark, PhD</name_or_title>
      <organization>New England Research Institutes, Inc.</organization>
      <phone>617-972-3362</phone>
      <email>pstark@neriscience.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

